JP2001503635A - Fasリガンドの変異体形態およびその使用 - Google Patents
Fasリガンドの変異体形態およびその使用Info
- Publication number
- JP2001503635A JP2001503635A JP52286498A JP52286498A JP2001503635A JP 2001503635 A JP2001503635 A JP 2001503635A JP 52286498 A JP52286498 A JP 52286498A JP 52286498 A JP52286498 A JP 52286498A JP 2001503635 A JP2001503635 A JP 2001503635A
- Authority
- JP
- Japan
- Prior art keywords
- fas ligand
- fas
- cells
- ligand
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.Fasリガンド欠失ムテインおよびFasリガンドキメラからなる群から選択され るFasリガンドアゴニストをコードするDNAであって、該Fasリガンド欠失ムテイ ンが、プロFasリガンド(配列番号12)の残基130位から始まる10〜17アミノ酸残 基の連続セグメントを欠くプロFasリガンドの欠失ムテインであって、該Fasリガ ンドキメラが、細胞表面タンパク質の切断不能な膜貫通ドメインのカルボキシ末 端とFasリガンドの細胞外ドメインのアミノ末端との間で融合された融合産物に 対応するアミノ酸配列を有する融合タンパク質であって、該細胞外ドメインが、 プロFasリガンドの残基130位から始まる10〜17アミノ酸残基の連続セグメントを 欠く、DNA。 2.Fasリガンド欠失ムテインまたはFasリガンドキメラをコードするDNAであっ て、該Fasリガンド欠失ムテインが、配列番号12の残基139あたりから残基146あ たりで始まるヒトFasリガンドのFas結合ドメインへの実質的に切断不能なペプチ ド結合によって連結されている、有効長の配列番号12の残基129までのFasリガン ドの膜貫通領域を含み、該Fasリガンドキメラが、配列番号12の残基139あたりか ら残基146あたりで始まるヒトFasリガンドのFas結合ドメインへの実質的に切断 不能なペプチド結合によって連結される細胞表面タンパク質の膜貫通領域を含む 、DNA。 3.配列番号5または配列番号7のDNA。 4.配列番号6または配列番号8のFasリガンドアゴニストをコードするDNA。 5.Fasリガンド欠失ムテインまたはFasリガンドキメラをコードする組換え遺伝 子に作動可能に連結されたプロモーターを含むベクターであって、該Fasリガン ド欠失ムテインが、配列番号12の残基139あたりから残基146あたりで始まるヒト FasリガンドのFas結合ドメインへの実質的に切断不能なペプチド結合によって連 結されている、有効長の配列番号12の残基129までのFasリガンドの膜貫通領域を 含み、該Fasリガンドキメラが、配列番号の残基139あたりから残基146あたりで 始まるヒトFasリガンドのFas結合ドメインへの実質的に切断不能なペプチド結合 によって連結される細胞表面タンパク質の膜貫通領域を含む、ベクター。 6.前記組換え遺伝子が前記Fasリガンド欠失ムテインをコードする、請求項5 に記載のベクター。 7.前記Fasリガンド欠失ムテインが、配列番号12における番号付に関して、130 6139、1306140、1306141、1306142、1306143、1306144、1306145、1306146、131 6140、1316141、1316142、1316143、1316144、1316145、および1316146からなる 群から選択される欠失を有する、請求項6に記載のベクター。 8.前記ベクターが、レトロウイルスベクター、アデノウイルスベクター、およ びアデノ随伴ベクターからなる群から選択される、請求項7に記載のベクター。 9.前記Fasリガンド欠失ムテインが1306142欠失を有する、請求項7に記載のベ クター。 10.前記Fasリガンド欠失ムテインが1306145欠失を有する、請求項7に記載の ベクター。 11.前記Fasリガンドキメラが、腫瘍壊死因子レセプタースーパーファミリー のメンバーから選択される膜貫通ドメインを有する、請求項6に記載のベクター 。 12.前記膜貫通ドメインが、肺瘍壊死因子レセプター、CD30、神経成長因子レ セプター、CD27、CD40、CD120a、CD120b、リンホトキシンβレセプター、 およびTRAILレセプターからなる群のメンバーから選択される、請求項11に記 載のベクター。 13.天然のFasリガンドより長く細胞膜上に残留し得るFasリガンドポリペプチ ドをコードする、ポリヌクレオチド。 14.Fasリガンド欠失ムテインおよびFasリガンドキメラからなる群から選択さ れるFasリガンドアゴニストであって、該Fasリガンド欠失ムテインが、プロFas リガンド(配列番号12)の残基130位から始まる10〜17アミノ酸残基の連続セグ メントを欠くプロFasリガンドの欠失ムテインであって、該Fasリガンドキメラが 、細胞表面タンパク質の切断不能な膜貫通ドメインのカルボキシ末端とFasリガ ンドの細胞外ドメインのアミノ末端との間で融合された融合産物に対応するアミ ノ酸配列を有する融合タンパク質であって、該細胞外ドメインが、プロFasリガ ンドの残基130位から始まる10〜17アミノ酸残基の連続セグメントを欠く、アゴ ニスト。 15.前記膜結合Fasリガンドムテインである、請求項14に記載のFasリガンド アゴニスト。 16.前記膜結合Fasリガンドムテインが、配列番号6または配列番号10のア ミノ酸配列と同様であるアミノ酸配列を有する、請求項15に記載のFasリガン ドアゴニスト。 17.前記膜結合Fasリガンドキメラからなる、請求項14に記載のFasリガンド アゴニスト。 18.前記キメラが、Fasリガンドの細胞外ドメインに融合された切断不能な膜 結合タンパク質の細胞内および/または膜貫通ドメインを含み、該細胞外ドメイ ンが配列番号12のプロFasリガンドの130位以上の残基で開始する、請求項14に 記載のFasリガンドアゴニスト。 19.前記キメラが、CD30の膜貫通ドメインのカルボキシ末端と残基130位〜147 位で始まるFasリガンドフラグメントのアミノ末端との間の融合産物に対応する アミノ酸配列を有する、請求項18に記載のFasリガンドアゴニスト。 20.前記キメラが、CD30の残基1〜86がそのアミノ末端で、Fasリガンドの残 基130〜281とそのカルボキシ末端で融合されたものに対応するアミノ酸配列を有 する、請求項19に記載のFasリガンドアゴニスト。 21.前記キメラが、CD40の膜貫通ドメインのカルボキシ末端と残基130位〜147 位で開始するFasリガンドフラグメントのアミノ末端との間の融合産物である、 請求項18に記載のFasリガンドアゴニスト。 22.前記キメラが、CD40の残基1〜107がそのアミノ末端で、Fasリガンドの残 基130〜281とそのカルボキシ末端で融合されたものに対応するアミノ酸配列を有 する、請求項21に記載のFasリガンドアゴニスト。 23.前記膜結合Fasリガンドムテインまたは前記膜結合Fasリガンドキメラが宿 主細胞の膜に結合している、請求項14に記載のFasリガンドアゴニスト。 24.前記宿主細胞がヒト宿主細胞である、請求項23に記載のFasリガンドア ゴニスト。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3087196P | 1996-11-13 | 1996-11-13 | |
US60/030,871 | 1996-11-13 | ||
US3997297P | 1997-02-10 | 1997-02-10 | |
US60/039,972 | 1997-02-10 | ||
US08/968,686 US6544523B1 (en) | 1996-11-13 | 1997-11-12 | Mutant forms of Fas ligand and uses thereof |
US08/968,686 | 1997-11-12 | ||
PCT/US1997/020864 WO1998021232A2 (en) | 1996-11-13 | 1997-11-13 | Mutant forms of fas ligand and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007299883A Division JP2008104464A (ja) | 1996-11-13 | 2007-11-19 | Fasリガンドの変異体形態およびその使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001503635A true JP2001503635A (ja) | 2001-03-21 |
Family
ID=27363738
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52286498A Ceased JP2001503635A (ja) | 1996-11-13 | 1997-11-13 | Fasリガンドの変異体形態およびその使用 |
JP2007299883A Pending JP2008104464A (ja) | 1996-11-13 | 2007-11-19 | Fasリガンドの変異体形態およびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007299883A Pending JP2008104464A (ja) | 1996-11-13 | 2007-11-19 | Fasリガンドの変異体形態およびその使用 |
Country Status (7)
Country | Link |
---|---|
US (3) | US6544523B1 (ja) |
EP (2) | EP0941238B1 (ja) |
JP (2) | JP2001503635A (ja) |
AT (1) | ATE417057T1 (ja) |
AU (1) | AU5258898A (ja) |
DE (1) | DE69739161D1 (ja) |
WO (1) | WO1998021232A2 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544523B1 (en) * | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US7070771B1 (en) | 1996-12-09 | 2006-07-04 | Regents Of The University Of California | Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells |
ATE460482T1 (de) | 1997-09-17 | 2010-03-15 | Mochida Pharm Co Ltd | Fas-liganden derivate |
US6451759B1 (en) | 1998-01-14 | 2002-09-17 | The Regents Of The University Of California | Noncleavable Fas ligand |
EP1082967B1 (en) * | 1998-05-29 | 2006-07-19 | Mochida Pharmaceutical Co., Ltd. | Prevention and treatment of autoimmune demyelinating diseases by Fas-antagonists |
EP0998945A1 (en) * | 1998-09-30 | 2000-05-10 | Transgene S.A. | Use of magnesium (Mg2+) for the enhancement of gene delivery in gene therapy |
AU761544C (en) * | 1999-05-24 | 2004-02-12 | Sankyo Company Limited | Medicinal compositions containing anti-Fas antibody |
WO2002072798A1 (en) * | 2001-03-13 | 2002-09-19 | Johns Hopkins University School Of Medicine | Fas ligand-expressing hematopoietic cells for transplantation |
EP1386155A4 (en) * | 2001-04-10 | 2006-05-10 | Univ Leland Stanford Junior | Therapeutic and diagnostic uses of antibody specificity profiles |
WO2003027242A2 (en) * | 2001-09-24 | 2003-04-03 | Duke University | Fas ligand |
US7786282B2 (en) * | 2001-12-06 | 2010-08-31 | The Regents Of The University Of California | Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain |
US20040131599A1 (en) * | 2002-03-13 | 2004-07-08 | Civin Curt I | Fas ligand expressing hematopoietic cells for transplantation |
US7495090B2 (en) * | 2002-05-23 | 2009-02-24 | The Regents Of The University Of California | Nucleic acids encoding chimeric CD154 polypeptides |
CN101875957A (zh) | 2004-12-30 | 2010-11-03 | 新加坡科技研究局 | 中国仓鼠凋亡相关基因 |
WO2008115569A1 (en) * | 2007-03-21 | 2008-09-25 | Cytologic, Inc. | Method for inhibiting immune responses in mammals using muteins of fas ligand |
US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
JP5963743B2 (ja) | 2010-04-23 | 2016-08-03 | ユニバーシティ オブ マサチューセッツ | Cnsターゲティングaavベクターおよびその使用方法 |
CA3050894C (en) | 2010-04-23 | 2022-10-18 | University Of Massachusetts | Multicistronic expression constructs |
CA2812057A1 (en) | 2010-09-28 | 2012-04-05 | Kahr Medical Ltd. | Compositions and methods for treatment of hematological malignancies |
EP2699680B1 (en) | 2011-04-21 | 2017-12-27 | University of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
US9657082B2 (en) | 2013-01-31 | 2017-05-23 | Thomas Jefferson University | PD-L1 and PD-L2-based fusion proteins and uses thereof |
EP3750907A3 (en) | 2014-03-18 | 2021-04-28 | University of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
US10711270B2 (en) | 2014-10-03 | 2020-07-14 | University Of Massachusetts | High efficiency library-identified AAV vectors |
WO2016054554A1 (en) | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
JP7023108B2 (ja) | 2014-10-21 | 2022-02-21 | ユニバーシティ オブ マサチューセッツ | 組み換えaavバリアントおよびその使用 |
US10584321B2 (en) | 2015-02-13 | 2020-03-10 | University Of Massachusetts | Compositions and methods for transient delivery of nucleases |
EP3285780A4 (en) | 2015-04-24 | 2018-12-19 | University of Massachusetts | Modified aav constructions and uses thereof |
US11253576B2 (en) | 2015-10-22 | 2022-02-22 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance in neurodegenerative disease |
WO2017136536A1 (en) | 2016-02-02 | 2017-08-10 | University Of Massachusetts | Method to enhance the efficiency of systemic aav gene delivery to the central nervous system |
WO2017139643A1 (en) | 2016-02-12 | 2017-08-17 | University Of Massachusetts | Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization |
US11413356B2 (en) | 2016-04-15 | 2022-08-16 | University Of Massachusetts | Methods and compositions for treating metabolic imbalance |
JP7493334B2 (ja) * | 2016-07-05 | 2024-05-31 | ユニバーシティ オブ マサチューセッツ | 緑内障における神経保護療法としてのsFasLのAAV2媒介遺伝子送達 |
US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
CA3040483A1 (en) | 2016-10-13 | 2018-04-19 | University Of Massachusetts | Aav capsid designs |
US11859179B2 (en) | 2017-05-09 | 2024-01-02 | University Of Massachusetts | Methods of treating amyotrophic lateral sclerosis (ALS) |
SG10201913147WA (en) | 2017-07-11 | 2020-02-27 | Compass Therapeutics Llc | Agonist antibodies that bind human cd137 and uses thereof |
CN118006607A (zh) | 2017-09-22 | 2024-05-10 | 马萨诸塞大学 | Sod1双表达载体及其用途 |
US20220175960A1 (en) * | 2018-08-24 | 2022-06-09 | Locanabio, Inc. | Fasl immunomodulatory gene therapy compositions and methods for use |
Family Cites Families (123)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US112492A (en) | 1871-03-07 | Improvement in hat-brushes | ||
US2386796A (en) | 1942-08-05 | 1945-10-16 | Bond Crown & Cork Co | Extruding device |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
US4551433A (en) | 1981-05-18 | 1985-11-05 | Genentech, Inc. | Microbial hybrid promoters |
US4411648A (en) | 1981-06-11 | 1983-10-25 | Board Of Regents, The University Of Texas System | Iontophoretic catheter device |
US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
ATE78293T1 (de) | 1983-05-27 | 1992-08-15 | Texas A & M Univ Sys | Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors. |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
DK518384A (da) | 1984-01-31 | 1985-07-01 | Idaho Res Found | Vektor til fremstilling af et gen-produkt i insektceller, fremgangsmaade til dens fremstilling samt dens anvendelse |
US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
DE3586772T2 (de) | 1984-07-24 | 1993-03-04 | Coselco Mimotopes Pty Ltd | Verfahren zur bestimmung von mimotopen. |
US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
US4762915A (en) | 1985-01-18 | 1988-08-09 | Liposome Technology, Inc. | Protein-liposome conjugates |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
IL77186A0 (en) | 1985-11-29 | 1986-04-29 | Touitou Elka | Pharmaceutical insulin composition |
US5091309A (en) | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4859609A (en) * | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4980289A (en) | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
WO1989001973A2 (en) | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
JP3015383B2 (ja) | 1987-09-11 | 2000-03-06 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 形質導入した線維芽およびそれらの使用 |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
IT1232969B (it) | 1987-11-27 | 1992-03-11 | Piaggio & C S P A Ora Piaggio | Trasmissione automatica per veicoli in genere. |
WO1989005349A1 (en) | 1987-12-09 | 1989-06-15 | The Australian National University | Method of combating viral infections |
CN1038306A (zh) | 1988-03-21 | 1989-12-27 | 维吉恩公司 | 重组反转录病毒 |
US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
US5206152A (en) | 1988-04-08 | 1993-04-27 | Arch Development Corporation | Cloning and expression of early growth regulatory protein genes |
US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
EP0432216A1 (en) | 1988-09-01 | 1991-06-19 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
ATE135397T1 (de) | 1988-09-23 | 1996-03-15 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
US5217879A (en) | 1989-01-12 | 1993-06-08 | Washington University | Infectious Sindbis virus vectors |
WO1990007936A1 (en) | 1989-01-23 | 1990-07-26 | Chiron Corporation | Recombinant therapies for infection and hyperproliferative disorders |
WO1990009441A1 (en) | 1989-02-01 | 1990-08-23 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
JP3140757B2 (ja) | 1989-02-06 | 2001-03-05 | デイナ・フアーバー・キヤンサー・インステイテユート | パッケージング欠陥hivプロウイルス、細胞系及びその使用 |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
ES2116269T3 (es) | 1989-03-21 | 1998-07-16 | Vical Inc | Expresion de secuencias exogenas de polinucleotidos en un vertebrado. |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
EP0487587A1 (en) | 1989-08-18 | 1992-06-03 | Chiron Corporation | Recombinant retroviruses delivering vector constructs to target cells |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5166057A (en) | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
EP0897987B1 (en) | 1989-10-24 | 2001-02-28 | Chiron Corporation | Secretion of human protein linked to gamma interferon signal peptide |
AU7007491A (en) | 1990-02-02 | 1991-08-08 | Schweiz. Serum- & Impfinstitut Bern | Cdna corresponding to the genome of negative-strand rna viruses, and process for the production of infectious negative-strand rna viruses |
NZ237464A (en) | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
GB9008687D0 (en) | 1990-04-18 | 1990-06-13 | Wright Machinery Co | Drive and monitoring system for a vibratory conveyor |
WO1991016116A1 (en) | 1990-04-23 | 1991-10-31 | Cellpro Incorporated | Immunoselection device and method |
US5252296A (en) | 1990-05-15 | 1993-10-12 | Chiron Corporation | Method and apparatus for biopolymer synthesis |
WO1991018088A1 (en) | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
IE66205B1 (en) | 1990-06-14 | 1995-12-13 | Paul A Bartlett | Polypeptide analogs |
WO1991019529A1 (en) | 1990-06-15 | 1991-12-26 | Cortrak Medical, Inc. | Drug delivery apparatus and method |
US5149655A (en) | 1990-06-21 | 1992-09-22 | Agracetus, Inc. | Apparatus for genetic transformation |
AU665176B2 (en) | 1990-09-21 | 1995-12-21 | Novartis Vaccines And Diagnostics, Inc. | Packaging cells |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
WO1992007945A1 (en) | 1990-10-30 | 1992-05-14 | Dana Farber Cancer Institute | Cell type specific alteration of levels of gene products in neural cells |
SE9003978D0 (sv) | 1990-12-13 | 1990-12-13 | Henrik Garoff | Dna expressionssystem baserade paa ett virus replikon |
AU657111B2 (en) | 1990-12-20 | 1995-03-02 | Dana-Farber Cancer Institute | Control of gene expression by ionizing radiation |
GEP19971086B (en) | 1991-02-22 | 1997-12-02 | Tillotts Pharma Ag | Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine |
US5851828A (en) | 1991-03-07 | 1998-12-22 | The General Hospital Corporation | Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells |
US5223408A (en) | 1991-07-11 | 1993-06-29 | Genentech, Inc. | Method for making variant secreted proteins with altered properties |
US5222936A (en) | 1991-09-25 | 1993-06-29 | Stephen Robert L | Intracorporeal iontophoretic method |
FR2681786A1 (fr) | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
WO1993010218A1 (en) | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
GB9125623D0 (en) | 1991-12-02 | 1992-01-29 | Dynal As | Cell modification |
FR2688514A1 (fr) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
JPH07507689A (ja) | 1992-06-08 | 1995-08-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 特定組織のターゲティング方法及び組成物 |
JPH09507741A (ja) | 1992-06-10 | 1997-08-12 | アメリカ合衆国 | ヒト血清による不活性化に耐性のあるベクター粒子 |
GB2269175A (en) | 1992-07-31 | 1994-02-02 | Imperial College | Retroviral vectors |
WO1994005369A1 (en) | 1992-08-28 | 1994-03-17 | Cortrak Medical, Inc. | Internal iontophoresis electrical circuit and waveforms |
DE69334238D1 (de) | 1992-09-25 | 2008-09-25 | Aventis Pharma Sa | Adenovirus vektoren für die übertragung fremder gene in zellen des zentralen nervensystems, insbesondere im gehirn |
ATE212665T1 (de) | 1992-11-18 | 2002-02-15 | Arch Dev Corp | Adenovirus gelenkter gen-transfer zum herz- und glatten vaskularen muskel |
EP0673431A1 (en) | 1992-12-03 | 1995-09-27 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5348358A (en) | 1993-02-22 | 1994-09-20 | Selick David A | Contact lens insertion tool |
DE4311651A1 (de) | 1993-04-08 | 1994-10-13 | Boehringer Ingelheim Int | Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen |
PT695169E (pt) | 1993-04-22 | 2003-04-30 | Skyepharma Inc | Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao |
EP0733122A4 (en) | 1993-05-26 | 1998-06-10 | Us Health | FUSION PROTEINS CONTAINING REP VIRUS PROTEIN ASSOCIATED WITH ADENOVIRUS AND BACTERIAL PROTEIN |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
ATE304604T1 (de) | 1993-06-24 | 2005-09-15 | Frank L Graham | Adenovirus vektoren für gentherapie |
ES2310924T3 (es) | 1993-07-13 | 2009-01-16 | Centelion | Vectores adenovirales defectivos y utilizacion en terapia genica. |
JPH09501564A (ja) | 1993-07-27 | 1997-02-18 | ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー | 改質dnaウイルスベクターおよびその使用 |
US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
EP0716148B1 (en) | 1993-09-15 | 2004-01-02 | Chiron Corporation | Recombinant alphavirus vectors |
FR2710536B1 (fr) | 1993-09-29 | 1995-12-22 | Transgene Sa | Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire. |
WO1995009654A1 (en) | 1993-10-01 | 1995-04-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gene therapy of the nervous system |
BR9407956A (pt) | 1993-10-25 | 1996-11-26 | Canji Inc | Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais |
JPH08127594A (ja) | 1993-11-10 | 1996-05-21 | Mochida Pharmaceut Co Ltd | Fas抗原に結合する新規蛋白質およびそれをコードするDNA |
RU2160093C2 (ru) | 1993-11-16 | 2000-12-10 | Скайефарма Инк. | Везикулы с регулируемым высвобождением активных ингредиентов |
FR2712603B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
ATE387458T1 (de) | 1994-01-07 | 2008-03-15 | Mochida Pharm Co Ltd | Fas-antigenbindender ligand |
JPH07241786A (ja) | 1994-03-08 | 1995-09-19 | Fanuc Ltd | 産業用ロボットの制御装置 |
US6780406B1 (en) | 1994-03-21 | 2004-08-24 | The Regents Of The University Of Michigan | Inhibition of vascular smooth muscle cell proliferation administering a thymidine kinase gene |
US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
JPH10507061A (ja) | 1994-04-28 | 1998-07-14 | ザ ユニバーシティ オブ ミシガン | アデノウイルス中にパッケージされたプラスミドdnaを用いる遺伝子送達ベクターおよびパッケージング細胞株 |
US5759536A (en) | 1994-05-27 | 1998-06-02 | University Technology Corporation | Use of fas ligand to supress T-lymphocyte-mediated immune responses |
EP0784690B1 (en) | 1994-06-10 | 2006-08-16 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
CZ293943B6 (cs) | 1994-08-02 | 2004-08-18 | Theágeneraláhospitalácorporation | Způsob výroby buňkyŹ která exprimuje membránově vázaný bílkovinný chimerní receptorŹ příbuzné molekuly a materiály |
FR2723588B1 (fr) | 1994-08-12 | 1996-09-20 | Rhone Poulenc Rorer Sa | Adenovirus comprenant un gene codant pour la glutathion peroxydase |
US5866402A (en) | 1995-05-05 | 1999-02-02 | Chiron Corporation | Chimeric MCP and DAF proteins with cell surface localizing domain |
GB9523469D0 (en) | 1995-11-16 | 1996-01-17 | Sandoz Ltd | Organic compounds |
US6046310A (en) | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
US6544523B1 (en) * | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
-
1997
- 1997-11-12 US US08/968,686 patent/US6544523B1/en not_active Expired - Fee Related
- 1997-11-13 EP EP97947531A patent/EP0941238B1/en not_active Expired - Lifetime
- 1997-11-13 AT AT97947531T patent/ATE417057T1/de not_active IP Right Cessation
- 1997-11-13 JP JP52286498A patent/JP2001503635A/ja not_active Ceased
- 1997-11-13 AU AU52588/98A patent/AU5258898A/en not_active Abandoned
- 1997-11-13 DE DE69739161T patent/DE69739161D1/de not_active Expired - Fee Related
- 1997-11-13 WO PCT/US1997/020864 patent/WO1998021232A2/en active Application Filing
- 1997-11-13 EP EP08018126A patent/EP2039768A1/en not_active Withdrawn
-
2003
- 2003-04-01 US US10/404,466 patent/US7393942B2/en not_active Expired - Fee Related
-
2007
- 2007-11-19 JP JP2007299883A patent/JP2008104464A/ja active Pending
-
2008
- 2008-06-30 US US12/165,601 patent/US20090239240A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20040126859A1 (en) | 2004-07-01 |
EP0941238A2 (en) | 1999-09-15 |
US7393942B2 (en) | 2008-07-01 |
EP2039768A1 (en) | 2009-03-25 |
DE69739161D1 (de) | 2009-01-22 |
US20090239240A1 (en) | 2009-09-24 |
ATE417057T1 (de) | 2008-12-15 |
JP2008104464A (ja) | 2008-05-08 |
US6544523B1 (en) | 2003-04-08 |
WO1998021232A3 (en) | 1998-07-09 |
AU5258898A (en) | 1998-06-03 |
WO1998021232A2 (en) | 1998-05-22 |
EP0941238B1 (en) | 2008-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7393942B2 (en) | Nucleic acids encoding mutant forms of Fas ligand | |
JP2008104464A5 (ja) | ||
US6297367B1 (en) | Polynucleotide encoding TNFL1 | |
WO1999033980A2 (en) | Members of tnf and tnfr families | |
JP4161084B2 (ja) | 腫瘍壊死因子関連リガンド | |
EP1767634A1 (en) | Novel galectin 8 modification protein and use thereof | |
JP2013162795A (ja) | ヒトサイクリン依存的キナーゼ(hPNQALRE) | |
WO1999033999A1 (en) | Mitogen-activated protein kinase kinase 7 (mkk7) | |
US5914266A (en) | Mammallian sex comb on midleg (mammalian SCM) acts as a tumor suppressor | |
US5948640A (en) | Mammalian additional sex combs (mammalian Asx) acts as a tumor suppressor | |
WO1999033990A1 (en) | HUMAN CXC CHEMOKINE (Tim-1) | |
JP2002511748A (ja) | アポトーシス誘導性ゲルゾリン配列 | |
WO1997042218A1 (en) | MAMMALIAN SEX COMB ON MIDLEG (MAMMALIAN Scm) ACTS AS AN ONCOGENE | |
WO1998039449A9 (en) | COMPOSITIONS AND USE OF M-CSF-alpha | |
JP2001517079A (ja) | M−CSFαの組成物および方法 | |
WO1999000499A1 (en) | Human fadd-interacting protein (fip) | |
ES2369502T3 (es) | Cinasa de tipo humano dependiente de ciclina (hpnqalre). | |
WO1999029850A1 (en) | HUMAN KISMET PROTEIN (hkis) ACTS AS AN ONCOGENE | |
WO1998057985A2 (en) | Human rip-interacting factor (rif) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070724 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071023 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071203 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071119 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081209 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20081203 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090420 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090609 |